Breast Cancer Chemoprevention Phase IB Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

Journal of Clinical Oncology - United States
doi 10.1200/jco.2004.22.14_suppl.1015
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Selective Estrogen Receptor Modulator Delivery of Quinone Warheads to DNA Triggering Apoptosis in Breast Cancer Cells

ACS Chemical Biology
BiochemistryMedicineMolecular Medicine
2009English

Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer

2013English

Phase I Trial of the Androgen Receptor Modulator CR1447 in Breast Cancer

Endocrine Connections
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2015English

The Selective Estrogen Receptor Modulator Raloxifene Inhibits Neutrophil Extracellular Trap Formation

Frontiers in Immunology
AllergyImmunology
2016English

Modulation of Estrogen-Depurinating DNA Adducts by Sulforaphane for Breast Cancer

2012English

Differential Estradiol and Selective Estrogen Receptor Modulator (SERM) Regulation of Keratin 13 Gene Expression and Its Underlying Mechanism in Breast Cancer Cells

Molecular and Cellular Endocrinology
BiochemistryEndocrinologyMolecular Biology
2008English

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

English

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy